MarketPulse

trial design

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Stock Collapses 80% on Failed Trial, Faces Securities Litigation

Gossamer Bio faces securities litigation after Phase 3 PROSERA trial failure triggered 80% stock decline, with allegations of investor deception regarding trial design and patient recruitment risks.
GOSSstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Gossamer Bio Plummets 80% as Failed Phase 3 Trial Triggers Securities Lawsuit

Gossamer Bio faces class action lawsuit after Phase 3 PROSERA trial failure causes 80% stock collapse. Allegations include investor misleading on trial design and patient recruitment.
GOSSsecurities class actionstock price drop
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Recursion Deepens Citeline Partnership to Supercharge AI Drug Discovery Platform

Recursion expands Citeline partnership to integrate real-world data into its AI drug discovery platform, achieving 30-60% trial enrollment improvements.
RXRXstrategic partnershipclinical development